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AbstrAct
Background No tools to predict the probability of 
extrahepatic disease progression (ePD) of initially 
unresectable, liver-limited metastatic colorectal cancer 
(mCRC) are currently available. To estimate the likelihood 
to develop ePD and to identify clinical and molecular 
factors that could predict extrahepatic progression-
free survival (ePFS), we conducted an observational, 
retrospective, multicentre cohort study.
Methods We retrospectively identified a cohort of 225 
patients with initially unresectable liver-limited disease 
(LLD), treated from January 2004 to December 2017 with 
first-line doublets or triplet plus a biological agent at two 
Italian institutions.
Results 173 (77%) patients experienced ePD which 
occurred within 1, 2 or 3 years from the diagnosis of 
mCRC in 15%, 49% and 66% of patients, respectively. 
Globally, 164 (73%) patients underwent a liver resection 
at some point of their disease history, and 54 (33%) of 
them underwent a subsequent locoregional treatment. 
Age > 70 years, locoregional nodal involvement at 
diagnosis of colorectal cancer and ≥4 liver metastases 
were significantly associated with higher risk of ePD while 
liver resections were associated with reduced risk of ePD. 
In the multivariable model, number of liver metastases 
(subdistribution HR, SHR 1.63, 95% CI 1.12 to 2.36; p = 
0.01) and liver resections (SHR 0.43, 95% CI 0.29 to 0.63; 
p = 0.001) were still associated with ePD. Number of liver 
metastases < 4, no nodal involvement at diagnosis and 
liver resections were also associated with prolonged ePFS.
Conclusions The identified clinical factors could 
help physicians in personalising the intensity and 
aggressiveness of liver-directed treatments in patients 
with mCRC with initially unresectable LLD.
IntRoduCtIon
Liver is the most frequent site of meta-
static spread from colorectal cancer (CRC) 
and appears as the only site of metastases 
in one-third of cases. Increasing evidence 
supports the crucial role of the multidiscipli-
nary management of these patients in order 
to offer them the most appropriate integra-
tion of systemic and locoregional interven-
tions.
Key questions
What is already known about this subject?
 ► Liver is the only site of metastases in one-third of 
patients with metastatic colorectal cancer (mCRC).
 ► Increasing evidence supports the crucial role of the 
multidisciplinary management of these patients in 
order to offer them the most appropriate integration 
of systemic and locoregional interventions with cu-
rative intent.
 ► No tools to predict the probability of extrahepatic 
disease progression (ePD) of initially unresectable, 
liver-limited mCRC are currently available.
What does this study add?
 ► To estimate the likelihood to develop ePD and to 
identify clinical and molecular factors that could 
predict extrahepatic progression-free survival, we 
conducted an observational, retrospective, multi-
centre cohort study.
 ► Age >70 years, locoregional nodal involvement at 
diagnosis of colorectal cancer and ≥4 liver metas-
tases were significantly associated with higher risk 
of ePD while liver resections were associated with 
reduced risk of ePD.
How might this impact on clinical practice?
 ► The identified clinical factors could help physicians 
in personalising the intensity and aggressiveness 
of liver-directed treatments in an oligometastatic 
setting.
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Surgery is regarded as the gold standard, since the 
radical resection of liver metastases is associated with 
prolonged overall survival (OS) as compared with non-cu-
rative or no liver resection,1 with a 5-year survival rate of 
25%2 and a similar 10-year survival rate,3 4 demonstrating 
that a small but not negligible fraction of patients achieves 
meaningful long-term benefit5 and sometimes cure from 
this approach.
However, about two-thirds of patients undergoing liver 
surgery for metastatic CRC (mCRC) experience disease 
recurrence and derive limited benefit from surgical 
approaches.
Several scoring systems have been developed to predict 
the risk of recurrence after the surgical resection of liver 
metastases based on clinical and pathological prognostic 
factors.2 6–19
In the last years, the therapeutic scenario for patients 
with mCRC with liver-limited disease (LLD) has notably 
changed. Indeed, active systemic regimens are now able 
to convert to resection a consistent percentage of initially 
unresectable patients with a 10-year survival rate around 
20%.4 In these patients, not only inducing cytoreduction 
but also achieving an adequate control of the micromet-
astatic disease is crucial to allow subsequent locoregional 
interventions and long-term disease control. Moreover, 
the options provided by the toolbox of locoregional 
therapies beyond surgical resection are more and more 
numerous, including thermoablation, intra-arterial 
chemotherapy, chemoembolisation or radioembolisation 
and stereotactic radiotherapy.20
The development of multiple tools and the lack of high 
levels of evidence about their proper use highlight the 
need to identify those patients who may benefit from 
these strategies in the modern therapeutic landscape. In 
fact, clinical experience reveals that patients with LLD 
at the time of metastases diagnosis may display hetero-
geneous disease behaviours: while in some patients, the 
metastases are confined to the liver during the natural 
history of the disease and across different lines of therapy; 
in other cases, the extrahepatic spread occurs early. By 
a clinical perspective, the adoption of locoregional 
approaches, including liver surgery, in the therapeutic 
route of patients with mCRC would be especially indi-
cated in the first scenario, and less effective in the latter.
So far, the weight of clinical and molecular prognostic 
factors on the probability to develop extrahepatic disease 
progression (ePD) has not been investigated. The present 
study aimed at estimating the likelihood to develop ePD 
and at identifying clinical, pathological and molecular 
factors associated with extrahepatic progression-free 
survival (ePFS) in patients with initially unresectable LLD 
mCRC.
MetHods
Patients’ population
We retrospectively identified a cohort of consecutive 
patients with mCRC with initially unresectable LLD 
treated with first-line chemotherapy doublets or triplet 
associated, when appropriate, with a biological agent, 
in two Italian institutions (Azienda Ospedaliera-Univer-
sitaria Pisana, Pisa, Italy and Fondazione IRCCS Istituto 
Nazionale dei Tumori, Milan, Italy) from January 2004 to 
December 2017.
Resectability of liver metastases was assessed at baseline 
by multidisciplinary teams at participating institutions 
considering both technical and biological criteria. Not 
only patients judged not technically resectable because 
of a high tumour burden but also those with technically 
resectable disease but with poor prognostic factors were 
included.
Data regarding clinical, molecular, and pathological 
features were collected at baseline. Information about 
treatments received, response including early tumour 
shrinkage and deepness of response obtained, and meta-
static sites were collected from medical clinical records at 
baseline and along the whole disease history until death 
or last follow-up.
Patients with extrahepatic involvement including 
suspected distant nodal involvement at diagnosis, concur-
rent or previous other malignancy within 5 years from 
mCRC diagnosis or with inadequate follow-up were 
excluded.
Additional information about liver resections, including 
applied techniques and surgical outcomes, and further 
liver procedures (surgery or other locoregional treat-
ments) were collected.
All clinical investigations detailed were conducted in 
accordance with the Declaration of Helsinki in compli-
ance with Good Clinical Practice.
statistical analysis
Baseline characteristics in patients undergoing at least 
one resection versus unresected patients were compared 
by means of χ2 test and Fisher’s exact test (when appro-
priate). The association of these characteristics with 
the probability of experiencing ePD was investigated by 
means of a competing risk assessment model at univari-
able and multivariable analyses based on Fine and Grey’s 
proportional subhazards method to estimate the abso-
lute risk of the occurrence of ePD through a cumulative 
incidence function increasing with time, considering as a 
competing event the occurrence of intrahepatic disease 
progression only.
ePFS was calculated from the day of mCRC diagnosis 
to the first observation of extrahepatic disease. Survival 
curves were estimated by the Kaplan-Meier method and 
compared with the log-rank test.
The impact of the collected information on ePFS was 
first assessed in univariate analyses. Significantly prog-
nostic variables (p<0.10) were included in a multivariable 
Cox proportional hazard model.
Moreover, to overcome a possible selection bias due 
to the retrospective nature of the observation and to the 
occurrence of liver resection at different times during 
patients’ disease histories, the Kernel smoothed hazard 
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Table 1 Baseline characteristics
Characteristics
Overall population
N=225
N (%)
Never resected
N=61
N (%)
At least one liver 
treatment
N=164
N (%) P value*
Age (years) 0.04 
 ≥70 38 (15) 16 (26) 22 (13)
 <70 187 (75) 45 (74) 142 (87)
ECOG PS <0.0001 
  1 30 (13) 49 (80) 18 (11)
  0 195 (87) 12 (20) 146 (89)
Timing 0.69 
  Synchronous 194 (86) 54 (89) 140 (85)
  Metachronous 31 (14) 7 (11) 24 (15)
Resected primary tumour 0.16 
  Yes 151 (67) 36 (59) 115 (70)
  No 74 (33) 25 (41) 49 (30)
Sidedness 0.21 
  Left 159 (71) 39 (64) 120 (73)
  Right 65 (29) 22 (36) 43 (26)
  Not available 1 (0) 0 (0) 1 (1)
Nodal involvement 0.10 
  Yes 114 (51) 32 (53) 82 (50)
  No 53 (24) 8 (13) 45 (27)
  Not available 58 (26) 21 (34) 37 (23)
Baseline CEA level 0.54 
 >200 ng/mL 49 (22) 16 (26) 33 (20)
 ≤200 ng/mL 128 (57) 34 (56) 94 (57)
  Not available 48 (21) 11 (18) 37 (23)
Number of liver metastases 0.002 
 ≥4 135 (60) 45 (74) 90 (55)
 <4 69 (31) 8 (13) 61 (37)
  Not available 21 (9) 8 (13) 13 (8)
Liver metastases maximum diameter 0.69 
 >30 mm 134 (60) 38 (62) 96 (58)
 ≤30 mm 65 (29) 16 (26) 49 (30)
  Not available 26 (11) 7 (12) 19 (12)
Bilobar involvement 0.22 
  Yes 153 (68) 43 (71) 110 (67)
  No 63 (28) 12 (20) 51 (31)
  Not available 9 (4) 6 (9) 3 (2)
Liver involvement <0.0001 
 >6 segments 49 (22) 26 (43) 23 (14)
 ≤6 segments 161 (71) 26 (43) 135 (82)
  Not available 15 (7) 9 (14) 6 (4)
Continued
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Characteristics
Overall population
N=225
N (%)
Never resected
N=61
N (%)
At least one liver 
treatment
N=164
N (%) P value*
RAS/BRAF status 0.13 
  Mutated 107 (48) 36 (59) 71 (43)
  Wild type 92 (41) 21 (34) 71 (43)
  Not available 26 (11) 4 (7) 22 (14)
Microsatellite status 1.00 
  MSI High 3 (1) 0 (0) 3 (2)
  MSI low/MSS 54 (24) 9 (14) 45 (27)
  Not available 168 (75) 52 (86) 116 (71)
Induction CT 0.31 
  Triplet 126 (56) 38 (62) 88 (54)
  Doublet 99 (44) 23 (38) 76 (46)
Biological agent 0.09 
  Anti-EGFR 57 (25) 13 (21) 44 (27)
  Anti-VEGF 132 (59) 38 (62) 94 (57)
  Both 11 (5) 6 (10) 5 (3)
  None 25 (11) 4 (7) 21 (13)
*P value for χ2 and Fisher’s exact test
Anti-EGFR, anti-epidermal growth factor receptor; Anti-VEGF, anti-vascular endothelial growth factor; CEA, carcinoembryonic antigen; CT, 
chemotherapy; ECOG, Eastern Cooperative Oncology Group; MSI, microsatellite instability; MSS, microstatellite stable; PS, Performance 
Status.
Table 1 Continued
model was applied to better estimate the relative contri-
bution of liver resection.
Results
Patients’ population
A cohort of 225 patients with initially unresectable 
liver-limited mCRC treated from January 2004 to 
December 2017 was identified. Among them, 187 
(75%) were younger than 70 years, 195 (87%) had an 
Eastern Cooperative Oncology Group Performance 
Status (ECOG-PS) 0, 194 (86%) of them presented with 
synchronous metastases, 114 (51%) had a documented 
locoregional nodal involvement at diagnosis, 135 (60%) 
had more than three liver metastases, 161 (71%) had 
less than six liver segments involved and in 134 (60%) 
patients the maximum diameter of liver lesions was 
higher than 30 mm. Information about RAS/BRAF status 
were available for 199 (89%) patients. Of these, 92 (41%) 
had RAS/BRAF wild-type disease, whereas 99 (50%) 
and 8 (4%) harboured RAS-mutated or BRAF-mutated 
tumours, respectively. Microsatellite status was known in 
only 57 (25%) cases, three (1%) of whom were defined as 
microsatellite instability (MSI) high and 54 (24%) were 
microsatellite stable (MSS)/MSI low. Patients’ character-
istics at the time of diagnosis of liver-limited mCRC are 
summarised in table 1. In all, 61 (27%) patients did not 
receive any liver-directed treatment in their therapeutic 
route, 164 (73%) underwent at least one locoregional 
liver treatment during their disease history and 54 (24%) 
of them underwent also a subsequent locoregional treat-
ment (figure 1A).
Patients’ outcomes
Overall, 52 (23%) patients including those who never 
progressed after a curative treatment were ePD free, 
during the whole period of observation and 173 (77%) 
experienced ePD which occurred within 1, 2 or 3 years 
from the diagnosis of mCRC in 15%, 49% and 66% of 
patients, respectively (figure 1B).
Among patients who were ePD free, five had obtained a 
complete response during the first-line treatment without 
experiencing disease progression and 22 never progressed 
after a curative liver resection. Among 198 patients who 
experienced at least one disease progression, 96 (48%) 
did not experienced ePD at first disease progression, and 
51 (53%) of them did not experienced ePD also at the 
second disease progression. In all, 34 (80%) of them did 
not experienced again ePD at the third disease progres-
sion. Baseline characteristics of the 34 patients with ePD 
free at third disease progression are summarised in online 
supplementary material table 1.
Among patients who received only one liver resection, 
ePD occurred within 1, 2 or 3 years from the first liver 
procedure in 37%, 54% and 65% of cases, respectively 
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Figure 1 ePD distribution. (A) Description of overall 
population. (B) ePD cumulative distribution through 
each year from diagnosis in overall population. (C) ePD 
cumulative distribution through each year from first liver 
resection in patients undergoing one secondary resection. 
() ePD cumulative distribution through each year from 
last liver procedure in patients undergoing more than 
one locoregional procedure. ePD, extrahepatic disease 
progression.
(figure 1C); similarly, in patients who underwent more 
than one locoregional procedure, ePD occurred in 37%, 
54% and 57% of patients within 1, 2 or 3 years, respec-
tively, from the last liver procedure (figure 1D).
Competing risk analysis and determinants of ePFs
Univariate analyses for competing risk revealed that age 
over 70 years (subdistribution HR, SHR 1.50, 95% CI 1.04 
to 2.18; p=0.03), nodal involvement at diagnosis (SHR 
1.50, 95% CI 1.01 to 2.22; p=0.04) and more than four 
liver metastases at baseline (SHR 1.79, 95% CI 1.28 to 
2.52; p=0.001) were significantly associated with higher 
risk for ePD. On the contrary, undergoing a liver resec-
tion was associated with lower risk of ePD (SHR 0.38, 95% 
CI 0.26 to 0.56; p=0.001). In the multivariable model, 
number of liver metastases (SHR 1.63, 95% CI 1.12 to 
2.36; p=0.01) and liver resections (SHR 0.43, 95% CI 0.29 
to 0.63; p=0.001) were still associated with ePD (online 
supplementary material table 2).
At the univariate analyses assessing the association 
between baseline characteristics and ePFS, age over 70 
years (HR 1.43, 95% CI 0.93-2.18; p=0.07), ECOG PS 1 
(HR 1.45, 95% CI 0.89 to 2.33; p=0.08), nodal involve-
ment at diagnosis (HR 1.55, 95% CI 1.08 to 2.23; p=0.03), 
more than four liver lesions (HR 1.67, 95% CI 1.22 to 
2.29; p=0.003), highest diameter of liver lesions >30 mm 
(HR 1.35, 95% CI 0.96 to 1.86; p=0.09), more than six liver 
segments involved (HR 1.40, 95% CI 0.94 to 2.09; p=0.06) 
and MSI high (HR 2.41, 95% CI 0.42 to 13.88; p=0.03) 
were associated with significantly shorter ePFS. On the 
contrary, undergoing a liver resection (HR 0.39, 95% CI 
0.26 to 0.59; p<0.001) and subsequent liver retreatments 
(HR 0.27, 95% CI 0.19 to 0.39; p<0.001) were associ-
ated with significantly longer ePFS. In the multivariable 
model, ECOG PS (HR 2.04, 95% CI 1.11 to 3.72; p=0.02), 
number (HR 1.83, 95% CI 1.15 to 2.90; p=0.01), diameter 
of liver lesions (HR 1.98, 95% CI 1.23 to 3.20; p=0.005) 
and undergoing a liver resection (HR 0.37, 95% CI 0.21 
to 0.65; p<0.001) were associated with ePFS (table 2).
A more accurate estimation of the impact of baseline 
characteristics on ePFS was obtained through the Kernel 
smoothed hazard estimator model to overcome the selec-
tion bias introduced by the occurrence of liver resec-
tion at different times during patients’ disease histories. 
Consistently with previously reported results, hepatic 
resections, no nodal involvement at diagnosis and less 
than four liver metastases were independently associated 
with prolonged ePFS when adjusted for the other signif-
icant variables (age, ECOG PS, diameter of liver lesions, 
number of involved segments) (figure 2).
In the subgroup of patients who did not undergo any 
liver procedure, the competing risk model could not 
be applied as all of them experienced ePD during their 
disease history. In this specific subgroup, ECOG PS 1 (HR 
2.19, 95% CI 0.95 to 5.06; p=0.01), baseline carcinoem-
bryonic antigen levels over 200 ng/mL (HR 1.82, 95% 
CI 0.91 to 3.64; p=0.03), >4 liver metastases (HR 2.61, 
95% CI 1.34 to 5.09; p=0.03) and highest diameter of 
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Table 2 Univariable and multivariable analyses for ePFS in the overall population
Characteristics
Univariable analyses Multivariable analyses
HR 95% CI P value HR 95% CI P value
Age ≥70 years versus <70 years 1.43 0.93 to 2.18 0.07 1.02 0.99 to 1.04 0.12
ECOG PS 1 versus 0 1.45 0.89 to 2.33 0.08 2.04 1.11 to 3.72 0.02
Synchronous versus metachronous 1.31 0.87 to 1.98 0.24 – – –
Resected primary tumour versus 
unresected
0.84 0.61 to 1.15 0.26 – – –
Left versus right primary 0.89 0.64 to 1.26 0.52 – – –
Nodal involvement versus no 
involvement
1.55 1.08 to 2.23 0.03 1.48 0.91 to 2.40 0.12
Baseline CEA level >200 versus ≤200 ng/
mL
1.19 0.80 to 1.77 0.37 – – –
Number of liver metastases ≥4 versus <4 1.67 1.22 to 2.29 0.003 1.83 1.15 to 2.90 0.01
Liver metastases maximum diameter >30 
versus ≤30 mm
1.35 0.96 to 1.86 0.09 1.98 1.23 to 3.20 0.005
Bilobar involvement yes versus no 1.14 0.82 to 1.58 0.44 – – –
Liver involvement >6 versus ≤6 segments 1.40 0.94 to 2.09 0.06 0.69 0.36 to 1.33 0.27
RAS/BRAF mutation versus RAS/BRAF 
wild type
1.11 0.82 to 1.51 0.67 – – –
MSI high versus MSS 2.41 0.42 to 13.88 0.03 -* -* -*
Triplet versus doublet induction 1.20 0.89 to 1.62 0.22 – – –
Anti-EGFR versus anti-VEGF 1.04 0.73 to 1.47 0.37 – – –
Liver secondary resection 0.39 0.26 to 0.59 <0.001 0.37 0.21 to 0.65 <0.001
Liver retreatments 0.27 0.19 to 0.39 <0.001 – – –
*Too small sample size for multivariable model
†Bold values represent statistically significant values.
Anti-EGFR, anti-epidermal growth factor receptor; Anti-VEGF, anti-vascular endothelial growth factor receptor; CEA, carcinoembryonic 
antigen; ECOG, Eastern Cooperative Oncology Group; MSI, microsatellite instability; MSS, microstatellite stable; PS, Performance Status; 
ePFS, extrahepatic progression-free survival.
liver lesions over 30 mm (HR 2.62, 95% CI 1.48 to 4.63; 
p=0.002) predicted shorter ePFS at univariate analyses. 
Left primary sidedness (HR 0.56, 95% CI 0.30 to 1.01; 
p=0.03) and previous primary resection (HR 0.60, 95% 
CI 0.34 to 1.05; p=0.05) were associated with prolonged 
ePFS. At the multivariate analysis, ECOG PS 1 (HR 2.68, 
95% CI 1.14 to 6.30; p=0.02) and highest diameter of liver 
metastases >30 mm (HR 3.03, 95% CI 1.29 to 7.12; p=0.01) 
were still associated with shorter ePFS (online supplemen-
tary material table 3). In the subgroup of patients who 
underwent at least one liver-directed procedure, nodal 
involvement (HR 1.55, 95% CI 1.02 to 2.36; p=0.04) and 
MSI-high status (HR 3.03, 95% CI 0.43 to 21.15; p=0.049) 
were associated with shorter ePFS while undergoing 
subsequent locoregional retreatments was associated with 
longer ePFS (HR 0.31, 95% CI 0.19 to 0.52; p<0.001). In 
the multivariable model, liver retreatments were still asso-
ciated with longer ePFS with a trend towards significance 
(HR 0.41, 95% CI 0.16 to 1.08; p=0.07) (online supple-
mentary material table 4).
dIsCussIon
The multidisciplinary management of mCRC substan-
tially contributed to the improvement of patients’ life 
expectancy and especially affected the prognosis of those 
with initially unresectable LLD whose treatment options 
have been substantially changed by the development 
and adoption of locoregional approaches.20 The present 
retrospective analysis provides an updated snapshot of 
the contemporary therapeutic route of patients affected 
by colorectal liver metastases. Notably, at least one liver 
locoregional procedure was performed at some point of 
the disease history in the vast majority (73%) of cases, and 
in the 33% of these, further locoregional interventions 
were reported.
When putting our results in the frame of available liter-
ature data, these percentages are extremely high, thus 
confirming the evolving scenario of systemic and local 
interventions’ integration at two Italian high-volume, 
referral centres.
In a previous historical pivotal series of 1439 consecutive 
patients with liver-limited mCRC enrolled from 1988 to 
1999, 1104 were considered as initially unresectable and 
were treated with systemic chemotherapy. Among them, 
only 138 (12.5%) underwent a liver resection demon-
strating that systemic treatment allows a small fraction of 
rescue liver surgeries with an OS at 10 years of 23%.21
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Figure 2 Cumulative incidence of ePD according to 
number of liver lesions and secondary resection and kernel 
smoothed hazard estimator for ePFS. CRC, colorectal 
cancer; ePFS, extrahepatic progression-free survival; n, 
number; Mets, liver metastases; HR, hepatic resection; N, 
nodal involvement.
Nonetheless, all patients included in our series were fit 
to receive a combination regimen as upfront treatment 
and were, therefore, able to achieve benefit from the 
most active systemic regimens. Moreover, only patients 
with strictly liver-limited, and not with liver-dominant 
spread were included in this cohort.
Resection rates of 32%, 49% and 61% were reported 
with doublets plus cetuximab, FOLFOX plus bevaci-
zumab and FOLFOXIRI plus bevacizumab, respectively, 
in contemporary phase II randomised trials investigating 
the efficacy of these regimens as conversion therapies.22 23
As compared with these controlled and prospective 
trials, not only patients who needed a relevant shrinkage 
to make liver resection feasible were included in our 
series but also those deemed initially unresectable based 
on biological considerations driven by disease aggressive-
ness and poor prognostic factors.
Based on our results, most of ePDs occurred within 3 
years from the last liver procedure, thus suggesting that 
tailored surveillance protocols should be adopted and, in 
particular, the intensification of clinical and radiological 
assessments may be justified in the first 2 years from liver 
curative approaches.
The paramount relevance of surgery with radical intent 
in favourably affecting the natural history of the disease is 
confirmed also in terms of ePFS. Also when applying the 
Kernel smoothed hazard estimator model, patients under-
going a liver surgery are less likely to develop extrahepatic 
metastases than unresected ones. Of note, all patients in 
the never resected subgroup experienced ePD at some 
time of their disease history, whereas patients under-
going repeated/sequential locoregional approaches may 
achieve a definitive cure.24
Indeed, our results suggest that the probability of expe-
riencing ePD through subsequent lines of treatment 
and disease progressions is numerically higher for those 
patients who never underwent liver resections compared 
with those who underwent at least one liver locoregional 
procedure.
With regard to other clinical and molecular factors, no 
nodal involvement at diagnosis and less than four liver 
metastases could affect the extrahepatic spread.
We acknowledge some limitations of our work, 
including the relatively small sample size and the retro-
spective collection of clinical data. Moreover, given the 
strong impact of a post-baseline variable, such as surgical 
resection, on the natural history of the disease and its 
progression patterns, this study did not allow developing 
and validating a score or a nomogram able to predict the 
risk of ePD at baseline. When focusing on the subgroup 
of patients who underwent at least one liver-directed 
procedure, the smaller sample size prevented to derive 
robust conclusions on ePD determinants, though high-
lighting the positive impact of subsequent liver re-treat-
ments on the extrahepatic spread. The clinical relevance 
of locoregional tools in the therapeutic route of patients 
with oligometastatic CRC is well described in the latest 
version of the European Society for Medical Oncology 
guidelines20 underlining the contribution of disease local-
isation, treatment goal, patient-related comorbidities and 
treatment morbility to the choice of the best approach in 
each individual case.
Though considering above-reported limitations, our 
findings may assist clinicians in intensifying liver-directed 
locoregional treatments in patients with LLD and could 
be useful also to select patients who may benefit from 
liver transplantation in the frame of ongoing prospective 
clinical studies. Similar considerations may be applied 
to other available liver-directed therapies in patients still 
deemed unresectable following conversion therapies. 
For example, radioembolisation prolongs intrahepatic 
PFS, but not intrahepatic plus extrahepatic overall PFS in 
patients with unresectable LLD with or without minimal 
extrahepatic disease.25
No association between molecular markers tested in 
the daily practice (ie, RAS/BRAF/MSI) and extrahepatic 
metastases was found. The association of BRAFV600E 
mutation with nodal and peritoneal spread is well known26 
and previous series evidenced short relapse-free and OS 
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following liver resection in the rare cases of LLD.27 28 
Our results are in line with a previous pooled analysis of 
patients with initially unresectable liver-limited mCRC 
treated in prospective clinical trials with FOLFOXIRI plus 
bevacizumab29 that is regarded by major international 
guidelines20 30 as the preferred therapeutic option, when 
feasible, to counterbalance the intrinsic biological aggres-
siveness of BRAF-mutated tumours.
Nevertheless, shorter ePFS (HR 2.41, 95% CI 0.42 to 
13.88; p=0.03) was reported in patients with MSI-high 
tumours versus MSS/MSI low. Due to the low prevalence 
of this alteration, especially in the case of LLD, these 
results should be cautiously interpreted, also taking into 
account the frequent co-occurrence of MSI and BRAF 
V600E mutation. Finally, the clarification of the surrogacy 
of ePFS for OS in liver-limited mCRC could be of interest 
in order to evaluate the potential role of ePFS as a new 
endpoint for clinical trials in this specific setting.
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